{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:24:44Z","timestamp":1772781884810,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.vaccine.2013.06.044","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T10:11:55Z","timestamp":1372155115000},"page":"3922-3927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost\u2013effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account"],"prefix":"10.1016","volume":"31","author":[{"given":"J.","family":"Luttjeboer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.A.","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"July (35)","key":"10.1016\/j.vaccine.2013.06.044_bib0005","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1016\/j.vaccine.2009.05.085","article-title":"Cost\u2013effectiveness of prophylactic vaccination against human papillomavirus 16\/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands","volume":"27","author":"Rogoza","year":"2009","journal-title":"Vaccine"},{"issue":"August (Suppl. 3)","key":"10.1016\/j.vaccine.2013.06.044_bib0010","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.06.044_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-11-0542","article-title":"Reducing HPV-associated cancer globally","volume":"5","author":"Lowy","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2013.06.044_bib0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2013.06.044_bib0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.vaccine.2013.06.044_bib0030","unstructured":"GlaxoSmithKline. Cervarix summary of product characteristics. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/20204\/SPC\/cervarix\/."},{"key":"10.1016\/j.vaccine.2013.06.044_bib0035","unstructured":"Causes of death; main primary causes of death, sex, age. Available from: www.statline.cbs.nl."},{"key":"10.1016\/j.vaccine.2013.06.044_bib0040","unstructured":"Dutch cancer Figures. Available from: http:\/\/cijfersoverkanker.nl\/?language=en."},{"issue":"October (46)","key":"10.1016\/j.vaccine.2013.06.044_bib0045","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost\u2013effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2013.06.044_bib0050","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"1","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2013.06.044_bib0055","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"15","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.06.044_bib0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2013.06.044_bib0065","series-title":"Decision modelling for health economic evaluation","author":"Brigg","year":"2006"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2013.06.044_bib0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/030089160909500203","article-title":"Incidence of invasive cervical cancer and direct costs associated with its management in Italy","volume":"95","author":"Ricciardi","year":"2009","journal-title":"Tumori"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2013.06.044_bib0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2010.09.030","article-title":"Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost\u2013effectiveness","volume":"47","author":"De Kok","year":"2011","journal-title":"Eur J Cancer"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2013.06.044_bib0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejogrb.2003.09.018","article-title":"Cost\u2013effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial","volume":"114","author":"Uyl-De Groot","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"October (7)","key":"10.1016\/j.vaccine.2013.06.044_bib0085","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.socscimed.2006.04.018","article-title":"Health care costs in the last year of life\u2014the Dutch experience","volume":"63","author":"Polder","year":"2006","journal-title":"Soc Sci Med"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2013.06.044_bib0090","article-title":"Cost\u2013effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening","volume":"141","author":"Wilschut","year":"2011","journal-title":"Gastroenterology"},{"issue":"May (8)","key":"10.1016\/j.vaccine.2013.06.044_bib0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ejca.2011.06.058","article-title":"Spatial variation in stage distribution in colorectal cancer in the Netherlands","volume":"48","author":"Elferink","year":"2012","journal-title":"Eur J Cancer"},{"issue":"October (20)","key":"10.1016\/j.vaccine.2013.06.044_bib0100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/jnci\/djp319","article-title":"Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening","volume":"101","author":"Lansdorp-Vogelaar","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"November (17)","key":"10.1016\/j.vaccine.2013.06.044_bib0105","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0959-8049(01)00292-1","article-title":"The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up","volume":"37","author":"van Agthoven","year":"2001","journal-title":"Eur J Cancer"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.06.044_bib0110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost\u2013effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2013.06.044_bib0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11912-005-0011-3","article-title":"Quality of life and gynecologic malignancies","volume":"7","author":"Sun","year":"2005","journal-title":"Curr Oncol Rep"},{"issue":"November (48)","key":"10.1016\/j.vaccine.2013.06.044_bib0120","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1016\/j.vaccine.2011.09.055","article-title":"The clinical benefit and cost\u2013effectiveness of human papillomavirus vaccination for adult women in the Netherlands","volume":"29","author":"Bogaards","year":"2011","journal-title":"Vaccine"},{"issue":"July","key":"10.1016\/j.vaccine.2013.06.044_bib0125","article-title":"Next generation cancer protection: the bivalent HPV vaccine for females","author":"Harper","year":"2011","journal-title":"ISRN Obstet Gynecol"},{"issue":"August (15)","key":"10.1016\/j.vaccine.2013.06.044_bib0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djp183","article-title":"Cost\u2013effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"101","author":"De Kok","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T03:39:54Z","timestamp":1563248394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13008232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":26,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0264410X13008232"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost\u2013effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}